(Durham, N.C.) Aldagen, Inc. today announced that a poster describing the homing properties of its cellular therapies was presented at the Seventh International Conference on Cell Therapy for Cardiovascular Disease. The data further explains the mechanism of action for Aldagen’s cell therapy products, and supports the ability of these cells to home to the site of ischemic injury. (more…)

(Research Triangle Park, N.C.) Mustard Tree Instruments®, a leader in analytical instrumentation for the pharmaceutical manufacturing industry, has launched a YouTube channel, YouTube.com/MustardTreeTV, to shine the spotlight on quality control issues leading to drug recalls and shortages in the United States and new applications of existing technology which can help solve this devastating problem. Additionally, the company has updated its seminal website, www.mustardtree.com, with new interactive features and information about its industry-renowned leadership team; at-line instrumentation products; and an overview of Raman spectroscopy. (more…)

(Cary, N.C.) CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $4.85 million financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures and Omega Funds all participated in the financing. CeNeRx plans to use the proceeds to complete its ongoing Phase II trial of the improved formulation of its novel antidepressant TriRima™ as monotherapy in treatment resistant depression, as well as to support advancement of its pipeline of promising agents for a variety of CNS disorders. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant. TC-5619 is a highly selective modulator of the alpha7 neuronal nicotinic receptor. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:

The Deutsche Bank 2011 BioFEST at the Four Seasons Hotel Boston on Monday, December 5, 2011 at 2:50 p.m. Eastern Time; and
The Oppenheimer & Co. 22nd Annual Healthcare Conference at The Waldorf=Astoria in New York City on Tuesday, December 13, 2011 at 2:05 p.m. Eastern Time. (more…)

(Research Triangle Park, N.C.) Todd Blonshine, CEO of Mustard Tree Instruments® addressed an audience of over 75 members of the pharmaceutical, life sciences, and affiliated market sectors in the Research Triangle Park region as the featured speaker for November’s Innovation in RTP event. In his presentation, “Drug Shortages and Recalls: Redefining Quality Control in the Pharmaceutical Manufacturing Industry with A Purpose” Blonshine discussed the challenges of quality control issues with raw materials in the drug manufacturing process and how his company is helping to alleviate the strain on manufacturers through its innovations in analytical testing instrumentation. (more…)

(Research Triangle Park, N.C.) Quintiles announced today that it has sold its minority interest in Invida, an Asia Pacific commercial solutions joint venture, to the Italy-based Menarini Group, which is acquiring Invida in its entirety. Invida was formed in 2006 by Quintiles; The Zuellig Group; and TLS Beta Pte. Ltd., an Asia investment company. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the Lazard Capital Markets 8th Annual Healthcare Conference at The Pierre Hotel in New York City on Tuesday, November 15, 2011 at 1:30 p.m. Eastern Time. (more…)

(Research Triangle Park, N.C.) Quintiles’ ability to provide customers with actionable early-stage data to make better development decisions faster has taken a significant step forward with the closing of the previously announced agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2011. (more…)

(Research Triangle Park, N.C.) Quintiles is ranked 25th in the inaugural World’s Best Multinational Workplaces list from the Great Place to Work® Institute. The rankings were announced during a reception at the New York Stock Exchange, hosted by the Great Place to Work Institute. (more…)

(Research Triangle Park, N.C.) To provide a more comprehensive and efficient global solution for its laboratory customers, Quintiles today announced the signing of a definitive agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory providing Good Laboratory Practice (GLP) pharmacokinetic/pharmacodynamic (PK/PD) testing and other services. Under the agreement, Quintiles will acquire Advion BioServices for an undisclosed amount of cash. Completion of the transaction, which is subject to usual and customary conditions, is expected this quarter. At that time it will join Quintiles as Advion Bioanalytical Labs, a Quintiles company. (more…)